{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:00:13Z","timestamp":1793944813861,"version":"4.8.0"},"reference-count":101,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"abstract":"<jats:sec id=\"ab-jsc260008-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) is a leading cause of acute respiratory tract infection and a contributor to morbidity and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc260008-2\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To synthesize evidence from recent randomized clinical trials and observational studies reporting on the effectiveness and safety of RSV vaccines and monoclonal antibodies and the epidemiology of RSV in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc260008-3\">\n                    <jats:title>Evidence Review<\/jats:title>\n                    <jats:p>Databases including MEDLINE (PubMed), Embase, Cochrane CENTRAL, and Scopus were searched from August 1, 2025, through June 29, 2026, for studies evaluating the safety and effectiveness of US-licensed RSV vaccines or RSV monoclonal antibody products or describing RSV epidemiology. Data were extracted for older adults (\u226560 years), adults, immunocompromised persons, infants, children, and individuals vaccinated during pregnancy. Reviewers assessed risk of bias (RoB) using Cochrane tools for randomized and observational studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc260008-4\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>A total of 75 eligible studies were identified, including 12 randomized clinical trials (RCTs), 33 observational studies with a comparator group, 16 observational studies without a comparator group, and 14 descriptive studies on RSV epidemiology. Among older adults, RSV vaccination was associated with a reduction in RSV-related hospitalization (vaccine effectiveness [VE], 83.3%; 95% CI, 42.9% to 96.9%). Point estimates for RSV VE against hospitalization and laboratory-confirmed RSV illness among older adults were significantly higher during the first season after vaccination compared with 12 to 18 months of follow-up in 1 study, although the difference was not significant when comparing VE after 1 season vs 2 seasons in another study. The VE for maternal vaccination (between 32-36 weeks\u2019 gestation) ranged from 51.0% (95% CI, \u221229.6% to 83.3%) to 70.0% (95% CI, 37.0% to 86.0%) against RSV-related infant hospitalization. Estimates for effectiveness of nirsevimab among infants varied by timing ranged from 63.6% (95% CI, 26.9% to 81.9%) to 93.0% (95% CI, 83.0% to 97.0%) for RSV-related hospitalization within 6 to 12 months. No cases of Guillain-Barr\u00e9 syndrome (GBS) were identified across 3 RCTs; among older adults, 1 self-controlled case series reported a possible increased risk of GBS during the 42 days following vaccination. None of the comparative studies included in this review found an association of RSV vaccination during pregnancy with preterm birth or other adverse pregnancy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jsc260008-5\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>RSV immunizations were associated with reduced risk of severe RSV and RSV-related hospitalizations; evidence among older adults suggests that RSV VE may be lower in subsequent seasons. Reported adverse events of special interest (including GBS and preterm birth) were consistent with prior reviews. The results of this updated review are both consistent with previously reported evidence and provide new insight into several aspects of RSV immunizations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2026.17871","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:30:17Z","timestamp":1788359417000},"source":"Crossref","is-referenced-by-count":2,"title":["RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season"],"prefix":"10.1001","author":[{"given":"Emily","family":"Senerth","sequence":"first","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyedeh Mahsa","family":"Sheikholeslamian","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeoluwa","family":"Babatunde","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Falk","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Watson","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harseerat","family":"Saini","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Tangri","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Lipson","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapeena","family":"Sivakumaran","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Wharton","sequence":"additional","affiliation":[{"name":"Oakwood Consulting, LLC, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah E.","family":"Moat","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare J.","family":"Stoddart","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle P.","family":"Walensky","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Division of Infectious Disease, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Vaccine Integrity Project, Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Basta","sequence":"additional","affiliation":[{"name":"Vaccine Integrity Project, Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis"},{"name":"Division of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Evidence Foundation, Cleveland Heights, Ohio"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"22","key":"jsc260008r2","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMsa2514268","article-title":"Updated evidence for Covid-19, RSV, and influenza vaccines for 2025-2026.","volume":"393","author":"Scott","year":"2025","journal-title":"N Engl J Med"},{"issue":"32","key":"jsc260008r3","doi-asserted-by":"publisher","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged =60 years: updated recommendations of the advisory committee on immunization practices\u2014United States, 2024.","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"41","key":"jsc260008r4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","article-title":"Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the advisory committee on immunization practices\u2014United States, 2023.","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"jsc260008r5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag117","article-title":"IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal RSV infections in immunocompromised patients.","author":"Tan","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"32","key":"jsc260008r7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.15585\/mmwr.mm7432a3","article-title":"Use of clesrovimab for prevention of severe respiratory syncytial virus\u2013associated lower respiratory tract infections in infants: recommendations of the advisory committee on immunization practices\u2014United States, 2025.","volume":"74","author":"Moulia","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"jsc260008r8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-073923","article-title":"Recommendations for the prevention of RSV disease in infants and children: policy statement.","volume":"156","author":"Committee on Infectious Diseases","year":"2025","journal-title":"Pediatrics"},{"issue":"71","key":"jsc260008r10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"jsc260008r15","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"jsc260008r16","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"11","key":"jsc260008r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1013723","article-title":"Clinical progression parameters associated with SARS-CoV-2, influenza, and respiratory syncytial virus infections in a large US integrated healthcare population.","volume":"21","author":"Parker","year":"2025","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"jsc260008r18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/cid\/ciaf194","article-title":"Respiratory syncytial virus co-detection with other respiratory viruses is not significantly associated with worse clinical outcomes among children aged &lt;2 years: New Vaccine Surveillance Network, 2016-2020.","volume":"82","author":"Amarin","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"11","key":"jsc260008r19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/INF.0000000000004866","article-title":"Clinical outcomes in children &lt;5 years of age hospitalized for respiratory syncytial virus, COVID-19 or influenza in the United States.","volume":"44","author":"Andersen","year":"2025","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"jsc260008r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.31499","article-title":"Clinical testing for COVID-19, influenza, and RSV in hospitalized youths, 2016-2024.","volume":"8","author":"Toepfer","year":"2025","journal-title":"JAMA Netw Open"},{"key":"jsc260008r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152846","article-title":"Outcomes of respiratory syncytial virus infection in patients with systemic autoimmune rheumatic disease.","volume":"75","author":"Enns","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"jsc260008r22","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70150","article-title":"Incidence rates of RSV-associated hospitalizations among adults in Middle Tennessee, United States, October 2022 through September 2023.","volume":"19","author":"Grijalva","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"key":"jsc260008r23","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2026.1808528","article-title":"Severe outcomes of individual or multiple respiratory viral infections in a large national healthcare system, 2022-2023.","volume":"14","author":"Grubber","year":"2026","journal-title":"Front Public Health"},{"issue":"14","key":"jsc260008r24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3201\/eid3114.241982","article-title":"Long-term illness in adults hospitalized for respiratory syncytial virus disease, United States, February 2022-September 2023.","volume":"31","author":"Leis","year":"2025","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"jsc260008r25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12879-026-12574-6","article-title":"Estimating the burden of RSV- and influenza-associated ED visits, hospitalizations, ICU admissions, and deaths across age and socioeconomic groups in New York State, 2005-2019.","volume":"26","author":"Xu","year":"2026","journal-title":"BMC Infect Dis"},{"issue":"2","key":"jsc260008r26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","article-title":"Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"67","author":"Liang","year":"2018","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"jsc260008r27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/infdis\/jiaf381","article-title":"Human metapneumovirus-, respiratory syncytial virus-, and influenza-associated pneumonia hospitalizations in Colorado adults aged =50 years, 2016-2023.","volume":"233","author":"Sim\u00f5es","year":"2026","journal-title":"J Infect Dis"},{"issue":"6","key":"jsc260008r28","doi-asserted-by":"publisher","first-page":"e1333","DOI":"10.1093\/cid\/ciaf710","article-title":"Long-term clinical outcomes after hospitalization for acute respiratory illness due to respiratory syncytial virus.","volume":"82","author":"Singer","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"4","key":"jsc260008r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.5695","article-title":"RSV prevention products and severe RSV-associated disease among infants.","volume":"9","author":"Bennett","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"4","key":"jsc260008r30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1473-3099(25)00624-3","article-title":"Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case-control study and cohort analysis.","volume":"26","author":"McLachlan","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"37","key":"jsc260008r31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.15585\/mmwr.mm7437a1","article-title":"Nirsevimab effectiveness against intensive care unit admission for respiratory syncytial virus in infants\u201424 States, December 2024-April 2025.","volume":"74","author":"Zambrano","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"jsc260008r32","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jama.2025.15405","article-title":"Bivalent RSV prefusion F protein-based vaccine for preventing cardiovascular hospitalizations in older adults: a prespecified analysis of the DAN-RSV trial.","volume":"334","author":"Lassen","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"jsc260008r33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2509810","article-title":"RSV prefusion F vaccine for prevention of hospitalization in older adults.","volume":"394","author":"Lassen","year":"2026","journal-title":"N Engl J Med"},{"issue":"1","key":"jsc260008r34","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.57187\/4711","article-title":"Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation.","volume":"156","author":"Shittu","year":"2026","journal-title":"Swiss Med Wkly"},{"issue":"16","key":"jsc260008r35","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1001\/jama.2025.15896","article-title":"RSV vaccine effectiveness against hospitalization among us adults aged 60 years or older during 2 seasons.","volume":"334","author":"Surie","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"jsc260008r36","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1093\/cid\/ciaf496","article-title":"Estimated vaccine effectiveness for respiratory syncytial virus-related acute respiratory illness in older adults: findings from the first postlicensure season.","volume":"82","author":"Tartof","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"2","key":"jsc260008r37","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3201\/eid3202.251520","article-title":"Effectiveness of RSV vaccines against RSV-associated thromboembolic events.","volume":"32","author":"Wiegand","year":"2026","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"jsc260008r38","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2026.2641671","article-title":"Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study.","volume":"25","author":"Fonseca","year":"2026","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"jsc260008r39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1473-3099(25)00546-8","article-title":"Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75-79 years in England: a multicentre, test-negative, case-control study.","volume":"26","author":"Symes","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"jsc260008r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105961","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness and antibody correlates of protection among older adults in the Community Vaccine Effectiveness (CoVE) observational study.","volume":"121","author":"Godonou","year":"2025","journal-title":"EBioMedicine"},{"issue":"1","key":"jsc260008r41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamainternmed.2025.6355","article-title":"Durability of respiratory syncytial virus vaccine effectiveness among US veterans.","volume":"186","author":"Bajema","year":"2026","journal-title":"JAMA Intern Med"},{"issue":"3","key":"jsc260008r42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamapediatrics.2025.5778","article-title":"Effectiveness and impact of maternal RSV immunization and nirsevimab on medically attended RSV in US children.","volume":"180","author":"Moline","year":"2026","journal-title":"JAMA Pediatr"},{"issue":"6","key":"jsc260008r43","article-title":"Evaluation of the effectiveness of the respiratory syncytial virus vaccine in children under 6 months of age in C\u00f3rdoba, Argentina.","volume":"123","author":"Scruzzi","year":"2025","journal-title":"Arch Argent Pediatr"},{"issue":"12","key":"jsc260008r44","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1097\/INF.0000000000004942","article-title":"Nirsevimab is effective against respiratory syncytial virus-associated hospitalization among American Indian and Alaska Native children in their first and second RSV seasons in Alaska and the Southwest United States, 2023-2024.","volume":"44","author":"Hammitt","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"jsc260008r45","doi-asserted-by":"publisher","DOI":"10.1177\/00333549261434117","article-title":"Factors affecting maternal respiratory syncytial virus vaccination and the impact on infant hospitalization during the 2023-2024 season in Dallas, Texas.","author":"Bailey","year":"2026","journal-title":"Public Health Rep"},{"issue":"2","key":"jsc260008r46","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.60735","article-title":"Respiratory syncytial virus vaccine and nirsevimab uptake among pregnant people and their neonates.","volume":"8","author":"Blauvelt","year":"2025","journal-title":"JAMA Netw Open"},{"key":"jsc260008r47","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwag200","article-title":"Respiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trial.","author":"Duus","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"jsc260008r48","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268825100782","article-title":"Monitoring effectiveness of nirsevimab immunization against RSV hospitalization using surveillance data: a test-negative case-control study, Spain, October 2024-March 2025.","volume":"154","author":"Campos Mena","year":"2025","journal-title":"Epidemiol Infect"},{"key":"jsc260008r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2026.101448","article-title":"Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes, a test-negative study in Quebec, Canada.","volume":"57","author":"Carazo","year":"2026","journal-title":"Lancet Reg Health Am"},{"issue":"9","key":"jsc260008r50","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jama.2025.24082","article-title":"Nirsevimab vs RSVpreF vaccine for respiratory syncytial virus-related hospitalization in newborns.","volume":"335","author":"Jabagi","year":"2026","journal-title":"JAMA"},{"issue":"1","key":"jsc260008r51","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2026.2649335","article-title":"Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: an observer-blinded, placebo-controlled, randomized, phase 3 trial.","volume":"22","author":"Comstock","year":"2026","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"jsc260008r52","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2579335","article-title":"Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59?years of age, including at-increased-risk adults: a randomized controlled trial.","volume":"21","author":"Ferguson","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"jsc260008r53","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag250","article-title":"Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged =60 years: a randomized, non-inferiority trial.","author":"Leroux-Roels","year":"2026","journal-title":"Clin Infect Dis"},{"key":"jsc260008r54","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag208","article-title":"Immunogenicity and safety of the adjuvanted respiratory syncytial virus prefusion F protein-based vaccine when co-administered with the adjuvanted recombinant herpes zoster subunit vaccine in adults = 50 years of age.","author":"Roussy","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"12","key":"jsc260008r55","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3390\/vaccines13121218","article-title":"Safety, tolerability, and immunogenicity of RSVpreF vaccine in pregnant individuals living with HIV.","volume":"13","author":"Myer","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"jsc260008r56","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/vaccines13080827","article-title":"Integrated analysis of the safety experience in adults with the bivalent respiratory syncytial virus prefusion F vaccine.","volume":"13","author":"Ilangovan","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"jsc260008r57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128566","article-title":"Maternal effectiveness of respiratory syncytial virus using multicenter healthcare records: a retrospective cohort study.","volume":"80","author":"Kitano","year":"2026","journal-title":"Vaccine"},{"issue":"1","key":"jsc260008r58","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2026.2637294","article-title":"Safety and health-related quality of life following maternal respiratory syncytial virus (RSV) and diphtheria-tetanus-acellular pertussis (DTaP) vaccinations.","volume":"22","author":"Kitano","year":"2026","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"jsc260008r59","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41541-026-01373-4","article-title":"Maternal safety outcomes of respiratory syncytial vaccination during pregnancy with a large-scale database.","volume":"11","author":"Kitano","year":"2026","journal-title":"NPJ Vaccines"},{"issue":"1","key":"jsc260008r60","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/AOG.0000000000006121","article-title":"Maternal and neonatal outcomes after respiratory syncytial virus prefusion f protein vaccination during pregnancy: analysis from the 2024-2025 immunization campaign in France.","volume":"147","author":"Gabet","year":"2026","journal-title":"Obstet Gynecol"},{"issue":"9","key":"jsc260008r61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-101592","article-title":"Perinatal outcomes and uptake of RSV vaccine during pregnancy in South London: a cross-sectional study.","volume":"15","author":"Razai","year":"2025","journal-title":"BMJ Open"},{"issue":"5","key":"jsc260008r62","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jama.2025.23452","article-title":"Interim safety of RSVpreF vaccination during pregnancy.","volume":"335","author":"Michnick","year":"2026","journal-title":"JAMA"},{"issue":"4","key":"jsc260008r63","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.6190","article-title":"Sequential safety surveillance of RSVpreF vaccination during pregnancy early in the postapproval period.","volume":"9","author":"Michnick","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"1","key":"jsc260008r64","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2550857","article-title":"Post-marketing safety monitoring of RSV vaccines: a real-world study based on the Vaccine Adverse Event Reporting System (VAERS).","volume":"21","author":"Bao","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"jsc260008r65","doi-asserted-by":"publisher","first-page":"129","DOI":"10.17161\/kjm.vol18.23980","article-title":"Adverse events reported following RSV prefusion F protein vaccines administration among approved populations: a cross-sectional study.","volume":"18","author":"McLaughlin","year":"2025","journal-title":"Kans J Med"},{"issue":"1","key":"jsc260008r66","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cmi.2025.09.013","article-title":"Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: an interventional cohort study.","volume":"32","author":"Hall","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"jsc260008r67","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127497","article-title":"Safety monitoring of Pfizer\u2019s respiratory syncytial virus vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States.","volume":"62","author":"Moro","year":"2025","journal-title":"Vaccine"},{"key":"jsc260008r68","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128547","article-title":"Adverse events after Pfizer\u2019s respiratory syncytial virus vaccine in pregnant women in the Vaccine Adverse Event Reporting System, 2024-2025, United States.","volume":"80","author":"Moro","year":"2026","journal-title":"Vaccine"},{"key":"jsc260008r69","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1682119","article-title":"Real-world feasibility of co-administration of RSV, COVID-19, and influenza vaccines in older adults: a VAERS-based analysis.","volume":"16","author":"Wei","year":"2025","journal-title":"Front Pharmacol"},{"issue":"5","key":"jsc260008r70","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1093\/cid\/ciag058","article-title":"Immunogenicity and safety of the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein vaccine in adults aged 18-49 years at increased risk of RSV disease compared with adults aged =60 years.","volume":"82","author":"Mitha","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"4","key":"jsc260008r71","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1093\/cid\/ciaf515","article-title":"Safety, tolerability, and immunogenicity of revaccination with mRNA-1345, an mRNA vaccine against respiratory syncytial virus, administered 12 months following a primary dose in adults aged =50 years.","volume":"82","author":"Goswami","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"9","key":"jsc260008r72","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.33828","article-title":"Respiratory syncytial virus vaccination in allogeneic hematopoietic stem cell transplant recipients.","volume":"8","author":"Redjoul","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"jsc260008r73","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3324\/haematol.2025.289242","article-title":"Attenuated antibody responses to respiratory syncytial virus vaccination in hematologic malignancies: impact of anti-CD20 therapy.","volume":"111","author":"Herishanu","year":"2026","journal-title":"Haematologica"},{"key":"jsc260008r74","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103767","article-title":"Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study.","volume":"92","author":"Sarwar","year":"2026","journal-title":"EClinicalMedicine"},{"issue":"6","key":"jsc260008r75","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-075223","article-title":"Maternal RSV vaccination, infant nirsevimab, or both: interim analysis of a randomized trial.","volume":"157","author":"Rostad","year":"2026","journal-title":"Pediatrics"},{"issue":"11","key":"jsc260008r76","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3390\/vaccines13111088","article-title":"RSV vaccination programme for older adults: a Scotland-wide study on RSVpreF vaccine safety.","volume":"13","author":"Cullen","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"jsc260008r77","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128459","article-title":"Safety monitoring of health outcomes following RSVPreF3 + AS01 and RSVPreF vaccination among Medicare beneficiaries aged 65 years and older in the United States, 2023-2024.","volume":"79","author":"Lloyd","year":"2026","journal-title":"Vaccine"},{"key":"jsc260008r78","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128493","article-title":"Self-reported reactogenicity of RSV vaccines among older adults: a post-licensure study within a large integrated healthcare system in Southern California.","volume":"79","author":"Malden","year":"2026","journal-title":"Vaccine"},{"key":"jsc260008r79","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127873","article-title":"Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink.","volume":"67","author":"Donahue","year":"2025","journal-title":"Vaccine"},{"key":"jsc260008r80","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128468","article-title":"Post-licensure safety monitoring of nirsevimab in Western Australia 2024.","volume":"79","author":"Strautins","year":"2026","journal-title":"Vaccine"},{"issue":"1","key":"jsc260008r81","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2026.2658377","article-title":"Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network.","volume":"22","author":"Vi\u00f1eta Paramo","year":"2026","journal-title":"Hum Vaccin Immunother"},{"key":"jsc260008r82","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127591","article-title":"Safety of timely immunization with nirsevimab in hospitalized preterm infants.","volume":"63","author":"Izquierdo","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"jsc260008r83","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/AOG.0000000000006130","article-title":"Maternal respiratory syncytial virus vaccination and preterm birth: a Utah statewide retrospective cohort study.","volume":"147","author":"Solsman","year":"2026","journal-title":"Obstet Gynecol"},{"issue":"3","key":"jsc260008r84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106600","article-title":"Effectiveness of a targeted infant RSV immunization strategy (2024-2025): a multicenter matched case-control study in a high-surveillance setting.","volume":"91","author":"Attaianese","year":"2025","journal-title":"J Infect"},{"issue":"10","key":"jsc260008r85","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1097\/INF.0000000000004878","article-title":"Maternal immunization with RSVpreF vaccine: effectiveness in preventing respiratory syncytial virus\u2013associated hospitalizations in infants under 6 months in Argentina: multicenter case\u2013control study.","volume":"44","author":"Gentile","year":"2025","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"jsc260008r86","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/INF.0000000000004920","article-title":"Second-season impact of nirsevimab: clinical outcomes of RSV disease in patients immunized during their first season.","volume":"44","author":"Gonz\u00e1lez-Bertol\u00edn","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"jsc260008r87","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101196","article-title":"Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis.","volume":"49","author":"Payne","year":"2025","journal-title":"Lancet Reg Health Am"},{"issue":"6","key":"jsc260008r88","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.16773","article-title":"Maternal respiratory syncytial virus prefusion f vaccination and acute respiratory illness in infants.","volume":"9","author":"Rick","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"16","key":"jsc260008r89","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2025.16744","article-title":"Respiratory syncytial virus vaccination in adult allogeneic hematopoietic cell transplant recipients.","volume":"334","author":"L\u00f6tscher","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"jsc260008r90","doi-asserted-by":"publisher","first-page":"11496","DOI":"10.1038\/s41467-025-66280-z","article-title":"Assessing the risk of Guillain-Barr\u00e9 syndrome in older adults after bivalent RSV pre-F vaccination in England.","volume":"16","author":"Stowe","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"jsc260008r91","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15585\/mmwr.mm7506a2","article-title":"Respiratory virus activity\u2014United States, July 1, 2024-June 30, 2025.","volume":"75","author":"Silk","year":"2026","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"jsc260008r92","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2026.101520","article-title":"Bivalent RSVpreF effectiveness against RSV-associated hospital or emergency department care over two seasons: a retrospective test-negative case control study.","volume":"60","author":"Tartof","year":"2026","journal-title":"Lancet Reg Health Am"},{"issue":"9","key":"jsc260008r93","article-title":"Efficacy and safety of respiratory syncytial virus vaccines.","volume":"9","author":"Saif-Ur-Rahman","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"jsc260008r94","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.8322","article-title":"Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 Years or older.","volume":"8","author":"Fry","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"jsc260008r97","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/pathogens13060503","article-title":"Comprehensive summary of safety data on nirsevimab in infants and children from all pivotal randomized clinical trials.","volume":"13","author":"Mankad","year":"2024","journal-title":"Pathogens"},{"issue":"26","key":"jsc260008r98","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants.","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med"},{"key":"jsc260008r99","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2026.2760","article-title":"Clesrovimab in infants at increased risk for severe disease during 2 RSV seasons: a randomized clinical trial.","author":"Zar","year":"2026","journal-title":"JAMA Pediatr"},{"key":"jsc260008r100","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128882","article-title":"Vaccine effectiveness of mRNA-1345 against RSV-associated hospitalization and medically attended acute respiratory illness among US veterans, 2025-2026.","volume":"88","author":"McConeghy","year":"2026","journal-title":"Vaccine"},{"issue":"5","key":"jsc260008r101","doi-asserted-by":"publisher","first-page":"734","DOI":"10.7326\/ANNALS-25-05485","article-title":"Respiratory syncytial virus vaccines in adults who are not pregnant or immunocompromised: rapid practice points from the American College of Physicians.","volume":"179","author":"Qaseem","year":"2026","journal-title":"Ann Intern Med"},{"key":"jsc260008r1","unstructured":"Centers for Disease Control and Prevention. Preliminary estimates of RSV burden. Published February 5, 2026. Accessed August 19, 2026. https:\/\/www.cdc.gov\/rsv\/php\/surveillance\/burden-estimates.html"},{"key":"jsc260008r6","unstructured":"American College of Obstetricians and Gynecologists. Maternal respiratory syncytial virus vaccination. Updated October 2025. Accessed July 19, 2026. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2023\/09\/maternal-respiratory-syncytial-virus-vaccination"},{"key":"jsc260008r9","unstructured":"Centers for Disease Control and Prevention. Catch-up immunization schedule for children and adolescents (addendum updated July 2, 2025). Published July 2, 2025. Accessed July 23, 2026. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/child-adolescent-catch-up.html"},{"key":"jsc260008r11","unstructured":"Covidence. Covidence systematic review software. Accessed August 13, 2026. http:\/\/www.covidence.org."},{"key":"jsc260008r12","unstructured":"US Food and Drug Administration. Vaccines licensed for use in the United States. Updated August 6, 2026. Accessed August 13, 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states"},{"key":"jsc260008r13","unstructured":"US Food and Drug Administration. What is a serious adverse event? FDA. Updated May 18, 2023. Accessed July 19, 2026. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"jsc260008r14","unstructured":"Google Workspace. Google Workspace: secure online productivity & collaboration tools. Accessed August 7, 2026. https:\/\/workspace.google.com\/intl\/en_ca\/"},{"key":"jsc260008r95","unstructured":"US Food and Drug Administration. FDA Requires Guillain-Barr\u00e9 Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy. Published January 7, 2025. Accessed August 7, 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-guillain-barre-syndrome-gbs-warning-prescribing-information-rsv-vaccines-abrysvo-and"},{"key":"jsc260008r96","unstructured":"US Food and Drug Administration. Package insert\u2014ABRYSVO (STN 125769). Updated December 2025. Accessed August 13, 2026. https:\/\/www.fda.gov\/media\/168889\/download"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2853780\/jama_senerth_2026_sc_260008_1790367710.69054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:02:31Z","timestamp":1790694151000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2853780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":101,"URL":"https:\/\/doi.org\/10.1001\/jama.2026.17871","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}